GlaxoSmithKlineE Beheer

Beheer criteriumcontroles 0/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Hassan Fahmi

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	geen gegevens

Recente managementupdates

Recent updates

CEO

Hassan Fahmi

no data

Tenure

Mr. Hassan Fahmi is Managing Director of GlaxoSmithKline S.A.E.

GlaxoSmithKlineE Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

No independent directors

No independent directors

Recent updates

Investor sentiment improves as stock rises 30%

Investor sentiment improves as stock rises 15%

Second quarter 2024 earnings released: EPS: ج.م1.22 (vs ج.م0.07 in 2Q 2023)

Upcoming dividend of ج.م0.75 per share

First quarter 2024 earnings released

New major risk - Revenue and earnings growth

New major risk - Financial data availability

Investor sentiment deteriorates as stock falls 19%

Full year 2023 earnings released

Investor sentiment improves as stock rises 17%

New major risk - Financial data availability

New major risk - Earnings quality

Upcoming dividend of ج.م0.75 per share at 2.3% yield

Investor sentiment improves as stock rises 23%

Investor sentiment deteriorates as stock falls 15%

Upcoming dividend of ج.م3.00 per share

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

No independent directors

Upcoming dividend of ج.م0.75 per share

No independent directors

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Upcoming dividend of ج.م0.50 per share

Hikma Pharmaceuticals PLC (LSE:HIK) cancelled the acquisition of GlaxoSmithKline S.A.E (CASE:BIOC).

Glaxo Group Receives Letter from ACDIMA for Acquisition of Glaxosmithkline Shares

Hikma Pharmaceuticals PLC (LSE:HIK) entered into a non-binding term sheet to acquire 91.2% stake in GlaxoSmithKline S.A.E (CASE:BIOC) from Glaxo Group Limited.

Investor sentiment improved over the past week

New 90-day high: ج.م19.35

New 90-day low: ج.م15.15

Third quarter 2020 earnings released: ج.م0.17 loss per share

New 90-day low: ج.م15.22

New 90-day high: ج.م18.34

New 90-day high - ج.م17.66

CEO

Tenure